Phase I study of the mitomycin C analogue BMS-181174.

Phase I study of the mitomycin C analogue BMS-181174.

BMS-181174 is an aminodisulphide derivative of Mitomycin C (MMC) with activity against a range of tumour cell lines and xenografts, including MMC-resistant tumours. In a phase I study of 82 patients with confirmed malignancy, we administered BMS-181174 at doses of 0.8-75 mg m(-2) by intravenous inje...

Full description

Bibliographic Details
Main Authors:	Macaulay, V. M., O'Byrne, K. J., Green, J. A., Philip, P. A., McKinley, L., LaCreta, F. P., Winograd, B., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Format:	Online
Language:	English
Published:	Nature Publishing Group 1998
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150373/

Similar Items

Characterization of a BMS-181174-resistant human bladder cancer cell line.
by: Xia, H., et al.
Published: (1997)

Dapagliflozin: BMS 512148; BMS-512148
Published: (2012)

The conformal BMS group
by: Sasha J. Haco, et al.
Published: (2017-11-01)

BRITOIL & BMS
Published: (1988)

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model
by: Leil, T A, et al.
Published: (2014)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
by: Propper, D. J., et al.
Published: (1998)

BMS supertranslations and not so soft gravitons
by: Eduardo Conde, et al.
Published: (2017-05-01)

B2BMS v FM
Published: (2001)

Generalizing the $$\mathfrak {bms}_{3}$$ bms3 and 2D-conformal algebras by expanding the Virasoro algebra
by: Ricardo Caroca, et al.
Published: (2018-03-01)

Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes.
by: Teicher, B. A., et al.
Published: (1985)

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.
by: O'Dwyer, P. J., et al.
Published: (1993)

BMS1 Is Mutated in Aplasia Cutis Congenita
by: Marneros, Alexander G.
Published: (2013)

Centrally extended BMS4 Lie algebroid
by: Glenn Barnich
Published: (2017-06-01)

BMS group at spatial infinity: the Hamiltonian (ADM) approach
by: Marc Henneaux, et al.
Published: (2018-03-01)

Asymptotic dynamics in perturbative quantum gravity and BMS supertranslations
by: Sangmin Choi, et al.
Published: (2018-01-01)

BMS and PC heads EC research programme
Published: (2000)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
by: Leil, T A, et al.
Published: (2014)

Variations in exposure to mitomycin C in an in vitro colony-forming assay.
by: Slee, P. H., et al.
Published: (1986)

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
by: O'Byrne, K. J., et al.
Published: (1994)

Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue.
by: Xu, B. H., et al.
Published: (1994)

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
by: Toyn, Jeremy H., et al.
Published: (2014)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
by: O'Byrne, K. J., et al.
Published: (1998)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
by: Frost, Charles E., et al.
Published: (2015)

A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
by: Ellis, P. A., et al.
Published: (1995)

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
by: Ellis, P. A., et al.
Published: (1995)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
by: Thompson, C. H., et al.
Published: (1996)

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
by: Datta, S. N., et al.
Published: (1997)

Comparison of coronary DES and BMS in octogenarians: A systematic review and meta-analysis
by: Gao, Lei, et al.
Published: (2013)

Integrable systems with BMS3 Poisson structure and the dynamics of locally flat spacetimes
by: Oscar Fuentealba, et al.
Published: (2018-01-01)

Cases Reported by Surgeon R. D. Murray, M.B. B.M.S.
Published: (1878)

The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
by: Keohane, A., et al.
Published: (1990)

Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.
by: van Geel, I. P., et al.
Published: (1995)

Mitomycin C. Current Status and Developments
by: Fox, B. W.
Published: (1980)

EFFECTS OF MITOMYCIN C ON HUMAN CHROMOSOMES
by: Cohen, Maimon M., et al.
Published: (1964)

Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax
by: Berger, A, et al.
Published: (2013)

Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study.
by: Baas, P., et al.
Published: (1996)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
by: Vakkalagadda, Blisse, et al.
Published: (2016)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
by: Frost, Charles, et al.
Published: (2013)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost, Charles, et al.
Published: (2014)

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
by: Golan, Talia, et al.
Published: (2015)